Sichuan Kelun-Biotech Biopharmaceutical Future Growth
Future criteria checks 2/6
Sichuan Kelun-Biotech Biopharmaceutical is forecast to grow earnings and revenue by 30.8% and 25.2% per annum respectively. EPS is expected to grow by 32.2% per annum. Return on equity is forecast to be -28.5% in 3 years.
Key information
30.8%
Earnings growth rate
32.2%
EPS growth rate
Biotechs earnings growth | 35.8% |
Revenue growth rate | 25.2% |
Future return on equity | -28.5% |
Analyst coverage | Good |
Last updated | 06 Jun 2024 |
Recent future growth updates
Recent updates
We Think Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) Can Easily Afford To Drive Business Growth
Jun 14Analysts Have Lowered Expectations For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) After Its Latest Results
Mar 27An Intrinsic Calculation For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Suggests It's 45% Undervalued
Jan 11Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 2,520 | -59 | -290 | 202 | 9 |
12/31/2025 | 1,510 | -609 | -702 | -466 | 11 |
12/31/2024 | 1,142 | -550 | -950 | -819 | 10 |
12/31/2023 | 1,540 | -522 | -23 | 60 | N/A |
9/30/2023 | 1,523 | -427 | 135 | 207 | N/A |
6/30/2023 | 1,505 | -333 | 292 | 355 | N/A |
3/31/2023 | 1,155 | -440 | -9 | 42 | N/A |
12/31/2022 | 804 | -548 | -310 | -271 | N/A |
12/31/2021 | 32 | -823 | -581 | -486 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6990 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6990 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6990 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6990's revenue (25.2% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 6990's revenue (25.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6990 is forecast to be unprofitable in 3 years.